CNS Pharmaceuticals Announces Shareholder Webinar to Discuss Collaboration with WPD Pharmaceuticals for Developing Coronavirus Drug Candidates, the Significance of WP1244, and an Update on the Cancer Free Survivor Treated with Berubicin

HOUSTON, April 15, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced that CEO, John M. Climaco, will be issuing a shareholder webinar on April 22nd, 2020 at 4:30pm ET to discuss the Company’s novel DNA-binding agent, WP1244, and to provide an update on both the development of WP1122 through its strong relationship with WPD Pharmaceuticals in Poland, and a glioblastoma survivor treated with Berubicin.

The release as fetched from its publisher. cnspharma.com ↗